SCYNEXIS, Inc. (SCYX)
Largest Insider Buys in Sector
SCYX Stock Price History Chart
SCYX Stock Performance
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the …
Insider Activity of SCYNEXIS, Inc.
Over the last 12 months, insiders at SCYNEXIS, Inc. have bought $27,400 and sold $0 worth of SCYNEXIS, Inc. stock.
On average, over the past 5 years, insiders at SCYNEXIS, Inc. have bought $261,559 and sold $4.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Angulo Gonzalez David (Chief Executive Officer) — $27,400.
The last purchase of 20,000 shares for transaction amount of $27,400 was made by Angulo Gonzalez David (Chief Executive Officer) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, SCYNEXIS, Inc.
| 2024-09-12 | Chief Executive Officer | 20,000 0.054% | $1.37 | $27,400 | +11.19% | |||
| 2022-04-26 | Chief Executive Officer | 75,000 0.226% | $3.00 | $225,000 | -8.26% | |||
| 2022-04-26 | General Counsel | 3,500 0.0105% | $3.00 | $10,500 | -8.26% | |||
| 2021-01-22 | Sale | 10 percent owner | 319,000 1.2567% | $8.24 | $2.63M | -12.08% | ||
| 2021-01-21 | Sale | 10 percent owner | 95,000 0.3717% | $7.38 | $701,100 | -2.46% | ||
| 2021-01-20 | Sale | 10 percent owner | 185,000 0.717% | $7.43 | $1.37M | -3.77% | ||
| 2020-12-21 | Chief Executive Officer | 40,000 0.3797% | $6.25 | $250,000 | +18.08% | |||
| 2020-12-21 | Chief Medical Officer | 1,600 0.0152% | $6.25 | $10,000 | +18.08% | |||
| 2020-12-21 | director | 8,000 0.0759% | $6.25 | $50,000 | +18.08% | |||
| 2020-12-21 | Chief Financial Officer | 600 0.0057% | $6.25 | $3,750 | +18.08% | |||
| 2020-12-21 | General Counsel | 1,600 0.0152% | $6.25 | $10,000 | +18.08% | |||
| 2020-12-21 | director | 8,000 0.0759% | $6.25 | $50,000 | +18.08% | |||
| 2020-12-21 | director | 5,000 0.0475% | $6.25 | $31,250 | +18.08% | |||
| 2020-12-21 | director | 4,000 0.038% | $6.25 | $25,000 | +18.08% | |||
| 2020-12-21 | director | 3,200 0.0304% | $6.25 | $20,000 | +18.08% | |||
| 2019-12-12 | Chief Executive Officer | 333,334 0.461% | $1.00 | $333,334 | -0.94% | |||
| 2019-08-21 | Chief Executive Officer | 19,000 0.0171% | $0.56 | $10,545 | -19.28% | |||
| 2019-08-20 | Chief Executive Officer | 1,000 0.0009% | $0.56 | $555 | -19.19% | |||
| 2019-08-15 | Chief Executive Officer | 20,030 0.0349% | $1.01 | $20,230 | -12.98% | |||
| 2019-04-17 | Chief Executive Officer | 50,000 0.095% | $1.63 | $81,500 | -32.30% |
Insider Historical Profitability
| Angulo Gonzalez David | Chief Executive Officer | 507871 1.3416% | $1.32 | 12 | 0 | +18.39% |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 1240575 3.277% | $1.32 | 1 | 0 | |
| Ventech Capital II | 10 percent owner | 414211 1.0942% | $1.32 | 1 | 0 | |
| Nothias Jean-Yves | director | 295077 0.7795% | $1.32 | 1 | 0 | |
| FCPR Biotechnology Fund | 10 percent owner | 295077 0.7795% | $1.32 | 1 | 0 |
Institutional Investor Ownership
| Federated Hermes | $6.2M | 11.16 | 4.21M | -12.28% | -$867,300.00 | 0.01 | |
| Kingdon Capital Management | $3.29M | 5.92 | 2.24M | 0% | +$0 | 0.44 | |
| The Vanguard Group | $2.48M | 4.47 | 1.69M | +8.29% | +$189,854.92 | <0.0001 | |
| Avidity Partners Management Lp | $2.13M | 3.84 | 1.45M | 0% | +$0 | 0.08 | |
| Amh Equity Ltd | $970,200.00 | 1.75 | 660,000 | +19.91% | +$161,112.00 | 1.26 |